| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Laninamivir (Inavir, CS-8958, R-125489) is a novel and potent neuraminidase inhibitor with antiviral activities. It inhibits avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2) strains with IC50s of 0.90 nM, 1.83 nM and 3.12 nM, respectively. Laninamivir exhibits clinical efficacy for both treatment and prophylaxis of influenza virus infection, resulting from hydrolytic bioactivation into its pharmacologically active metabolite laninamivir in the pulmonary tissue.
| Targets |
N5(IC50= 0.90 nM);p09N1(IC50= 1.83 nM);p57N2(IC50= 3.12 nM)
|
|---|---|
| ln Vitro |
Common oseltamivir-resistant viruses, including those with the common His274Tyr substitution, are effectively inhibited by laninamivir (R 125489)[1].
Like Zanamivir, laninamivir (R 125489) has a similar binding mechanism and is effective against p57N2, p09N1, and N5[1].
|
| References |
| Molecular Formula |
C13H22N4O6
|
|---|---|
| Molecular Weight |
346.33638
|
| Exact Mass |
346.15
|
| Elemental Analysis |
C, 45.08; H, 6.40; N, 16.18; O, 32.34
|
| CAS # |
203120-17-6
|
| Related CAS # |
Laninamivir octanoate;203120-46-1;Laninamivir octanoate hydrate;1233643-88-3
|
| Appearance |
Solid powder
|
| SMILES |
O=C(C1=C[C@H](NC(N)=N)[C@@H](NC(C)=O)[C@@H](C[C@@H](OC)CO)O1)O
|
| InChi Key |
LANWZBLPTYVJPY-PKIKSRDPSA-N
|
| InChi Code |
InChI=1S/C13H22N4O6/c1-6(19)16-11-8(17-13(14)15)4-10(12(20)21)23-9(11)3-7(5-18)22-2/h4,7-9,11,18H,3,5H2,1-2H3,(H,16,19)(H,20,21)(H4,14,15,17)/t7-,8+,9-,11-/m1/s1
|
| Chemical Name |
(2R,3R,4S)-3-acetamido-4-guanidino-2-((R)-3-hydroxy-2-methoxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid
|
| Synonyms |
CS8958; CS-8958; CS 8958;R-125489; R 125489; R125489;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~14.44 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.12 mg/mL (9.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8873 mL | 14.4367 mL | 28.8734 mL | |
| 5 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL | |
| 10 mM | 0.2887 mL | 1.4437 mL | 2.8873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
